RT Journal Article
T1 Evolutionary Origins of Metabolic Reprogramming in Cancer
A1 García-Sancha, Natalia
A1 Corchado-Cobos, Roberto
A1 Gómez-Vecino, Aurora
A1 Jiménez-Navas, Alejandro
A1 Pérez-Baena, Manuel Jesús
A1 Blanco-Gómez, Adrián
A1 Holgado-Madruga, Marina
A1 Jian-Hua, Mao
A1 Cañueto, Javier
A1 Castillo Lluva, Sonia
A1 Mendiburu-Eliçabe Garganta, Marina
A1 Pérez-Losada, Jesús
AB Metabolic changes that facilitate tumor growth are one of the hallmarks of cancer. These changes are not specific to tumors but also take place during the physiological growth of tissues. Indeed, the cellular and tissue mechanisms present in the tumor have their physiological counterpart in the repair of tissue lesions and wound healing. These molecular mechanisms have been acquired during metazoan evolution, first to eliminate the infection of the tissue injury, then to enter an effective regenerative phase. Cancer itself could be considered a phenomenon of antagonistic pleiotropy of the genes involved in effective tissue repair. Cancer and tissue repair are complex traits that share many intermediate phenotypes at the molecular, cellular, and tissue levels, and all of these are integrated within a Systems Biology structure. Complex traits are influenced by a multitude of common genes, each with a weak effect. This polygenic component of complex traits is mainly unknown and so makes up part of the missing heritability. Here, we try to integrate these different perspectives from the point of view of the metabolic changes observed in cancer.
SN 1422-0067
YR 2022
FD 2022-10-11
LK https://hdl.handle.net/20.500.14352/100436
UL https://hdl.handle.net/20.500.14352/100436
LA eng
NO García-Sancha N, Corchado-Cobos R, Gómez-Vecino A, Jiménez-Navas A, Pérez-Baena MJ, Blanco-Gómez A, et al. Evolutionary Origins of Metabolic Reprogramming in Cancer. IJMS 2022;23:12063. https://doi.org/10.3390/ijms232012063.
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Agencia Estatal de Investigación
NO Comisión Europea
NO Junta de Castilla y León
NO Ministerio de Economía, Comercio y Empresa (España)
NO Federación Española de Enfermedades Raras
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 14 may 2026